Emmanuel Dejean
Vorstandsvorsitzender bei Calixar SAS
Profil
Emmanuel Dejean is the founder of Calixar SAS, a company founded in 2011.
He currently holds the title of Chairman & Chief Executive Officer at Calixar SAS.
Dr. Dejean has a doctorate degree from Université de Montpellier and an undergraduate degree from Institut National Polytechnique de Grenoble.
Aktive Positionen von Emmanuel Dejean
| Unternehmen | Position | Beginn |
|---|---|---|
Calixar SAS
 Calixar SAS Miscellaneous Commercial ServicesCommercial Services Calixar SAS provides services for the production, extraction, and purification of functional membrane proteins. It offers protein sequence analysis and design optimization, protein expression/production, extraction/solubilization/purification/stabilization, structural and functionality tests, scale-up, crystallography tests, and 3D structure determination services. The firm provides its services for drug and target, vaccine, and antibody discovery applications. The company was founded by Emmanuel Dejean and Pierre Falson in January 2011 and is headquartered in Lyon, France. | Vorstandsvorsitzender | 01.01.2011 |
Ausbildung von Emmanuel Dejean
| Université de Montpellier | Doctorate Degree |
| Institut National Polytechnique de Grenoble | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Calixar SAS
Calixar SAS Miscellaneous Commercial ServicesCommercial Services Calixar SAS provides services for the production, extraction, and purification of functional membrane proteins. It offers protein sequence analysis and design optimization, protein expression/production, extraction/solubilization/purification/stabilization, structural and functionality tests, scale-up, crystallography tests, and 3D structure determination services. The firm provides its services for drug and target, vaccine, and antibody discovery applications. The company was founded by Emmanuel Dejean and Pierre Falson in January 2011 and is headquartered in Lyon, France. | Commercial Services |
